SCHEMBL279659

SCHEMBL279659

Cc1ccc(/C=C/C2CCNCC2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.39
MAPT P10636 5/20 0.39
NPC1 O15118 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
KHK P50053 1/20 0.37
HPGD P15428 2/20 0.33
XBP1 P17861 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 3/20 0.33
RECQL P46063 2/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280165 0.71 NOS1 (0.32) SMN1; SMN2KHKKCNH2
SCHEMBL12307008 0.71 MAPT (0.61) RAB9AMAPTNPC1SMN1; SMN2CASP3
SCHEMBL13226178 0.71 MAPT (0.61) RAB9AMAPTNPC1SMN1; SMN2CASP3
SCHEMBL6956559 0.71 HTR2C (0.46) MAPTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL6011041 0.70 MAOB (0.51) RAB9AMAPTNPC1SMN1; SMN2KMT2A
SCHEMBL30683539 0.70 MAOB (0.51) RAB9AMAPTNPC1SMN1; SMN2KMT2A
SCHEMBL2535218 0.69 HTR2C (0.46) KHKHTR2C
SCHEMBL2535222 0.69 HTR2C (0.46) KHKHTR2C
SCHEMBL2535408 0.69 HTR2C (0.46) KHKHTR2C
Hydrochloric Acid SCHEMBL27035873 0.69 MAOB (0.50) RAB9AMAPTNPC1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL RAB9A 2458/4885MAPT 311/4885NPC1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.